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A Novel Frameshift Mutation in Exon 23 of ATP7A (MNK) Results
in Occipital Horn Syndrome and Not in Menkes Disease
Susan L. Dagenais,* Ayla N. Adam,* Jeffrey W. Innis, and Thomas W. Glover
Departments of Pediatrics and Human Genetics, University of Michigan, Ann Arbor
Menkes disease and occipital horn syndrome (OHS) are allelic, X-linked recessive copper-deficiency disorders
resulting from mutations in ATP7A, or MNK. Classic Menkes disease has a severe phenotype, with death in early
childhood, whereas OHS has a milder phenotype, with, mainly, connective-tissue abnormalities. Data suggest that
steady-state localization of ATP7A to the trans-Golgi network (TGN) is necessary for proper activity of lysyl
oxidase, which is the predominant cuproenzyme whose activity is deficient in OHS and which is essential for
maintenance of connective-tissue integrity. Recently, it was reported that ATP7A-transcript levels as low as 2%–5%
of normal are sufficient to result in the milder phenotype, OHS, rather than the phenotype of Menkes disease. In
contrast to previously reported cases of OHS, we describe a case of OHS in which, because of a frameshift mutation,
no normal ATP7A is produced. Although abundant levels of mutant transcript are present, there are substantially
reduced levels of the truncated protein, which lacks the key dileucine motif L1487L1488. It has been demonstrated
that the dileucine motif L1487L1488 functions as an endocytic signal for ATP7A cycling between the TGN and
the plasma membrane. The present report is the first to describe an ATP7A truncation that results in OHS rather
than in Menkes disease. The data from the present report support the concepts that (1) OHS results from lower
levels of functional ATP7A and (2) ATP7A does not require the dileucine motif to function in copper efflux.
Menkes disease (MIM 309400) and occipital horn syn-
drome (OHS [MIM 304150]) are allelic, X-linked re-
cessive copper-deficiency disorders (Levinson et al. 1993;
Das et al. 1995) resulting from mutations in ATP7A,
or MNK (GenBank accession number NM_000052)
(Chelly et al. 1993; Mercer et al. 1993; Vulpe et al.
1993). ATP7A contains 23 exons that span a genomic
region of ∼140 kb (Dierick et al. 1995; Tu¨mer et al.
1995) and has a predominant transcription product of
∼8.5 kb (Chelly et al. 1993; Mercer et al. 1993; Vulpe
et al. 1993). ATP7A is ∼170 kD in size and is a member
of the P-type–ATPase family (Chelly et al. 1993; Mercer
et al. 1993; Vulpe et al. 1993). P-type ATPases transport
cations across cellular membranes by using energy gen-
erated by ATP hydrolysis (Pedersen et al. 1987). ATP7A
functions (a) to transport copper from the gastrointes-
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tinal tract into the bloodstream, (b) to efflux excess cop-
per from the cell, and (c) for intracellular delivery, within
the secretory pathway, of copper to cuproenzymes (for
reviews, see Kaler 1998; Camakaris et al. 1999; Harris
2000). At basal intracellular copper levels, the steady-
state localization of ATP7A is to the trans-Golgi Net-
work (TGN) (Petris et al. 1996; Yamaguchi et al. 1996;
Dierick et al. 1997). However, in an environment with
excess copper, ATP7A is transported, via secretory ves-
icles, to the plasma membrane, where it functions to
efflux copper from the cell (Petris et al. 1996, 1999; La
Fontaine et al. 1998). In response to intracellular cop-
per levels, it is believed that ATP7A cycles between the
TGN and the plasma membrane. The dileucine motif
L1487L1488 functions as an endocytic signal for ATP7A
cycling (Petris et al. 1998, 1999; Francis et al. 1999)
and is necessary for internalization of the protein from
the plasma membrane (Francis et al. 1999). However,
data from Petris et al. (1998) suggest that the dileucine
motif L1487L1488 is not necessary for ATP7A to func-
tion in copper efflux.
Classic Menkes disease is a rare multisystem disorder
with a severe phenotype including neonatal neurological
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403del98nt No … Deletion in regulatory region, normal transcript level,
reduced CAT activity
Levinson et al. (1996)
IVS62del(taag) Yes Donor Exon 6 skippedrframeshiftrPTC, reduced normal
transcript level
Møller et al. (2000), Gu et al. (2001)
2055CrT Yes … Exon 8 skippedrframeshiftrPTC, exons 8–10
skipped, reduced transcript level with S637L
Ronce et al. (1997)
IVS103art Yes Donor Exon 10 skippedrin-frame deletionrdeletion of
transmembrane domains 3 and 4 in protein,
abundant abnormal transcript level
Qi and Byers (1998)
2642ArG Yes Donor Exon 11 skippedrframeshiftrPTC, exons 11 and 12
skippedrframe-shiftrPTC, reduced transcript level
with S833G
Kaler et al. (1994)
IVS144arg Yes Acceptor Exon 15 skippedrin-frame deletionrdeletion of
transduction domain, abundant abnormal
transcript level, reduced normal transcript level
Das et al. (1995)
IVS175gra Yes Donor Exon 17 skippedrframeshiftrPTC, reduced normal
transcript level
Das et al. (1995), Levinson et al. (1993)
4497–4499delG No … FrameshiftrPTC, abundant abnormal transcript level Present study
a IVS p intervening sequence.
Figure 1 Pedigree, consistent with X-linked inheritance, of the
family with OHS. Family members included in this study were II-6,
III-1, III-2, and III-3. Blackened squares indicate affected males, and
unblackened squares indicate unaffected males. Circles with a dot in-
dicate carrier females, and circles without a dot indicate either unaf-
fected or untested females.
degeneration, hypopigmentation, skin and joint laxity,
coarse and twisted hair (pili torti), hypothermia, seizures,
failure to thrive, and death typically by the age of 3 years
(Menkes et al. 1962). In patients with Menkes disease,
abnormal, or nonfunctional, ATP7A results in decreased
intestinal absorption of copper, which leads to decreased
copper in the plasma, liver, and brain (for review, seeKaler
1998). The clinical phenotype of Menkes disease can be
attributed to the reduced activity of several cuproenzymes,
such as lysyl oxidase, tyrosinase, copper/zinc superoxide
dismutase, dopamine b-hydroxylase, and cytochrome c
oxidase (Menkes 1988). In addition, it has been dem-
onstrated that there is an accumulation of copper in cer-
tain tissues and cell types, which indicates that ATP7A in
these patients is not functioning properly to efflux copper
from the cell (for review, see Kaler 1998). Thus, at the
tissue level, Menkes disease can be considered a disorder
of copper maldistribution.
OHS, formerly known as “X-linked cutis laxa” or
“Ehlers-Danlos syndrome type 9,” has a phenotype
milder than that of Menkes disease, mainly composed
of connective-tissue manifestations, including skin lax-
ity, hyperextensible joints, bladder diverticula, charac-
teristic occipital exostoses, and, occasionally, mild neu-
rological involvement (Lazoff et al. 1975; Byers et al.
1980; for review, see Tsukahara et al. 1994). Byers et
al. (1980) demonstrated that patients with OHS have
decreased activity of the cuproenzyme lysyl oxidase,
which functions in the initiation of cross-linking of both
collagen and elastin. It has been hypothesized that OHS
results from the presence of low levels of functional
ATP7A, unlike Menkes disease, in which no normal
ATP7A activity exists (Das et al. 1995). This hypothesis
has been supported by a recent study that demonstrates
that ATP7A-transcript levels as low as 2%–5% of nor-
mal are sufficient to result in themilder phenotype,OHS,
as opposed to Menkes disease (Møller et al. 2000). It
has been postulated that lysyl oxidase is more sensitive
than other cuproenzymes to copper deficiency, thus re-
sulting in decreased lysyl oxidase activity in patientswith
OHS (Das et al. 1995; Levinson et al. 1996).
There are 35–40 known cases of OHS worldwide
(Møller et al. 2000), but mutations in only 8 cases have
been elucidated at the molecular level (table 1). In seven
of these eight cases, themutation leads to aberrant splicing
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Table 2






Promoter tcaatggagggaagaggat gaaaagagagcgactggtca 579
1 tgaggtgttatgagtttcttcacaagc gaatcacagcattctttcaagaggtc 312
2 aggggaaaagttgaggaaag ggcatttgacttcagtttcca 241
3 cttcttgaatgtggtgtgatg gccttacaaaacaatcaacacc 588
4 caacagaatgttttctgaagtagccc gcaaaagtggaattacagtgcctatg 904
5 aaggatgcaattgaatgatcaatactg cattactgaaaatcatgaggccttacc 384
6 ttatgaagcaaggtgataggtacgtca tttaaattccatgcttgaagagtacca 606
7 ttaagatcttgtgtggcaaacc aaccagaaatgattcacgggagt 615
8 aaagattggaaacaaatgcaatcaag ttgtgaccatttcatccagtataagga 356
9 tccttatactggatgaaatggtcacaa tctttcttaggggttaaatggcatcta 534
10 gcttgtgcagcaatttgaatacct aagcatgtatttccaatgattggc 282
11 gctgtcttttgggtaaatgctaaagat gacaaaatggatagatgaagtatggca 351
12 cttccattggcagtaattatggagc gccacaaagtaaatctgaggaaattg 402
13 aaggtttatattcctggcattggc ttgtctgcaaactgctggatagg 909
14 aagaggcacaaacatcaaaggtaactt aaaccatgtcagaaatgagactaagca 960
15 ctggaatctcagtatgtcccaatttc tctgtctttctgccacaaagactagtc 695
16 ttgaggcactagaggcgtctctt aacaccgagctagatttgatccg 576
17 cttgctaatgaatgaccttgcattatc aatgatcagaaggcatagggtattgac 427
18 tgaacatcactgttggaggctatg gcattcaagatgcttttgataaccc 399
19 catgccctgaacaactttacttgag aacagaaattggtgtacagtgtcacg 506
20 ttgctcagttatgtttcacgtactc ttgaagatcattttattccgaatcca 535
21 cttcggaagctgagtctaagttttagc gaagacaggcttccaatatgttaggtc 353
22 caaacattcttatgtctgtgaaaacc gaatggtttgggcttatcattgatc 610
23 atcttctttcttttctgcatgtagcg AAGATATTTTTGCCAACAGATAAACGC 515
a Lowercase letters denote that primer is in the intron, and uppercase letters denote that primer is in the noncoding
region of the exon.
of the ATP7A transcript (Kaler et al. 1994; Das et al.
1995; Ronce et al. 1997; Qi and Byers 1998; Møller et
al. 2000; Gu et al. 2001). In four of the cases of OHS
with a splice mutation, low levels of normal transcript
have been detected (Levinson et al. 1993; Das et al. 1995;
Møller et al. 2000; Gu et al. 2001). Missense mutations
in two reported cases of OHS resulted in aberrant splicing
of the transcript with an amino acid change in the normal
transcript, which did not adversely affect the function of
ATP7A (Kaler et al. 1994; Ronce et al. 1997). Qi and
Byers (1998) did not detect normal ATP7A transcript by
reverse-transcription PCR (RT-PCR) in a family with
OHS with a splice mutation in intron 10. However, it is
possible that the affected members of that family could
produce a low level of normal ATP7A, similar to that
produced in affected members of a family described by
Møller et al. (2000). In addition, Levinson et al. (1996)
described a patient with OHS who did not have a mu-
tation in the coding region of ATP7A but, instead, had
a 98-bp deletion in the regulatory region of ATP7A.
Northern analysis indicated normal transcript levels;
however, a chloramphenicol acetyltransferase (CAT) re-
porter assay suggested that the promoter deletion would
result in decreased expression of ATP7A.
In the present report, we describe a frameshift mu-
tation in a family with classic OHS. The mutation is
novel—that is, it does not result in aberrant splicing of
the transcript, as has been seen in seven of the eight
previously reported mutations. In our case, no normal
ATP7AmRNA is transcribed, owing to a frameshift mu-
tation at codon 1451, which leads to premature trun-
cation of the predicted protein. Because the protein was
truncated prior to L14871488 in the carboxy terminus,
it provides insight as to the importance, with respect to
phenotype, of this signal.
The pedigree of this family with classic OHS reveals a
pattern of affected individuals that is consistent with X-
linked inheritance (fig. 1). The proband (III-2) sat without
assistance at the age of 7 mo and was able to crawl at
the age of 7.5 mo. On examination, he exhibited multiple
bladder diverticula, renal calculus, vesicoureteral reflux,
bilateral inguinal hernia repair, neurogenic bladder, genu
valgum, and pectus excavatum; he also had mildly hyper-
elastic skin, especially over the abdomen, and required
special education. He did not exhibit chronic diarrhea,
orthostatic hypotension, or dysautonomic symptoms. A
skeletal survey of this individual revealed bilateral occip-
ital horns, mild lower-thoracic and lumbar platyspondyly,
marked pectus excavatum, broad scapular necks, clavic-
ular handlebar/hammer contour, humeral and femoral di-
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Figure 2 Frameshift mutation in ATP7A. The 5′ and 3′ UTRs of the ∼8.5-kb ATP7A transcript are shown atop a gray background, and
the 4.5-kb coding region is shown without a background. In the lower portion of the figure, the coding sequence of wild-type (wt) ATP7A
exon 23 is enlarged. The wild-type guanine triplet at positions 4497–4499 is shown atop a black background. The BslI (ccnnnnnnngg) restriction
site is shown above the wild-type nucleotide sequence. Conceptual translation of wild-type (without background) and mutant (atop a gray
background) ATP7A is illustrated below the nucleotide sequence. The dileucine motif L1487L1488 is underlined in wild-type ATP7A. Stop
codons are indicated by asterisks (*).
aphyseal wavy contour, bulbous ulnar-coronoid and ra-
dial bowing of the forearms, rounded iliac-wing contour
with broadening in the medial/lateral dimension, bilateral
coxa valga, and minimal dextroconvex scoliosis from T4
to L4. At the age of 8 years, III-2’s serum copper level
was slightly low, at 60 mg/dl (normal range 70–150 mg/
dl), as was the serum ceruloplasmin level, which was 18.9
mg/dl (normal range 20–42 mg/dl). At the age of 10 years
9 mo, he was given the Woodcock-Johnson Tests of Cog-
nitive Ability, the Woodcock-Johnson Tests of Achieve-
ment, the Wechsler Individual Achievement Test, the
Bender Gestalt Test, and the Human Figure Drawing
Task. For the Wechsler Individual Achievement Test, he
had scores that were age equivalent to 8 years 3 mo in
basic reading, 8 years in math reasoning, and 8 years 6
mo in spelling. He had a standard score of 84 for the
Woodcock-Johnson Tests of Cognitive Ability, which is
in the low-average range. III-2’s affected brother (III-3),
maternal uncle (II-10), and cousin (II-5) were similarly
affected but with slight variability in severity. The pattern
of inheritance and the clinical findings were consistent
with a diagnosis of OHS.
After obtaining informed consent, we collected skin
biopsies and blood samples from III-2, III-3, III-2’s un-
affected brother (III-1), and their carrier mother (II-6),
in accordance with the procedures of the institutional
review boards of the University of Michigan Medical
School. Fibroblast and Epstein-Barr virus–transformed
lymphoblastoid cell lines were generated and cultured
according to standard procedures.
To determine whether, in our case, the mutation in-
volved a splice site, we performed RT-PCR. PCR prod-
ucts were generated using cDNA reverse transcribed
from total RNA (SuperscriptII Reverse Transcriptase;
GibcoBRL) and eight primer pairs that spanned the cod-
ing region of ATP7A. No novel aberrant splicing was
detected by RT-PCR (not shown), suggesting that in both
III-2 and III-3 the mutation was not due to a splice
mutation.
To identify the mutation, we sequenced ATP7A at the
genomic level. By use of the DNAeasy TissueKit (Qiagen),
genomic DNAwas isolated from lymphoblastoid cell lines
from each family member studied and from an unrelated
normal male control cell line. PCR products for each exon
were generated from the genomic DNA of both III-2 and
the control by intronic primer pairs for each of the 23
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Figure 3 Mutation analysis of the family with OHS. To generate
515-bp PCR products (upper panel), the exon 23 primer pair (table
2) and genomic DNAs isolated from lymphoblastoid cell lines from
an unrelated normal control (wt), II-6, III-1, III-2, and III-3 were used.
Digests in III-2, III-3, and in one allele of II-6 demonstrate loss of 312-
bp and 119-bp BslI fragments (lower panel). The presence, in all di-
gests, of the 84-bp fragment indicates complete digestion with BslI.
The smallest band in the digest for II-6 is a primer band and is also
present in the water blank.
Figure 4 Northern blot analysis of ATP7A-transcript levels.
TRIZOL (Gibco) was used to isolate total RNA from lymphoblastoid
cell lines from II-6, III-1, III-2, and III-3. mRNA was obtained using
the PolyATtract mRNA Isolation System IV (Promega). A northern
blot containing 2 mg of poly(A) from each family member was hy-
bridized with a [32P]-radiolabeled 1.2-kb cDNAprobe, specific to exons
4–10 (nucleotides 1147–2335) of ATP7A. The primer sequences used
to generate, via RT-PCR, the 1.2-kb product of normal lymphoblastoid
cDNA were 5′- AATAGTGGCTGTATCACCGGG-3′ and 5′- GTACC-
AGCCTCCGAAAAACTG-3′. Subsequent hybridization with a [32P]-
radiolabeled b-actin probe (Clontech) demonstrated loading consis-
tency of poly(A) RNA, in each lane (lower panel). Probes were
radiolabeled by the rediprimeII Random Prime Labeling System
(Amersham Pharmacia Biotech).
exons and the 98-bp triple repeat in the promoter region
(table 2). PCR products were subcloned into TA-cloning
vector pCR2.1 (Invitrogen) and were sequenced, by use
of an ABI model 373XL automated sequencer, by the
University of Michigan DNA Sequencing Core. II-6, III-
1, III-2, and III-3 all had the 98-bp triple repeat in the
promoter region, indicating that the mutation in this fam-
ily was not similar to the OHS-promoter mutation de-
scribed by Levinson et al. (1996). A frameshift mutation
was identified in exon 23 of III-2 and, subsequently, in
both III-3 and II-6. A single guanine nucleotide was de-
leted from a guanine triplet (fig. 2, black background) at
nucleotides 4497–4499 of ATP7A, in III-2 and III-3 and
in one allele of II-6; an unrelated normal control and III-
1 and the other allele of II-6 all contained the guanine
triplet at these nucleotide positions. Conceptual transla-
tion of III-2’s ATP7A gene (fig. 2, mutant, gray back-
ground) shows a frameshift at codon 1451, resulting in
a carboxy terminus with 13 novel amino acids before
premature truncation of the protein. The truncated pro-
tein lacks the dileucine motif L1487L1488 (fig. 2, wt,
underlined), which functions as an endocytic signal (Petris
et al. 1998; Francis et al. 1999).
The mutation was confirmed by restriction analysis,
since the guanine deletion results in the loss of a BslI
(ccnnnnnnngg) restriction site (fig. 2). PCR products of
515 bp (fig. 3, upper panel) were generated from ge-
nomic DNA by the exon 23 primer pair given in table
2. The PCR products were digested with BslI for 3 h at
55C and then were resolved by electrophoresis through
a 2% agarose gel (fig. 3, lower panel). Normal genomic
DNA has two BslI restriction sites within this PCR prod-
uct and, after digestion, generates fragment sizes of 312
bp, 119 bp, and 84 bp. These fragments were detected
in the control (wt), II-6, and III-1. II-6, III-2, and III-3
had digestion products of 431 bp and 84 bp, which
indicated a loss of the BslI restriction site.
Despite the presence of the frameshift mutation, the
transcript levels in III-2, III-3, and II-6 were determined,
by northern blot analysis, to be either normal or some-
what increased (fig. 4). It is known that nonsense and
frameshift mutations introduce premature-termination
codons (PTCs) into open reading frames, which typically
leads to rapid degradation, by the nonsense-mediated
decay (NMD) process, of the affectedmRNA (for review,
see Frischmeyer and Dietz 1999). However, when a PTC
occurs in the last exon of the gene, the mRNA may not
be subject to NMD (Thermann et al. 1998), thus likely
explaining why abundant transcript levels are present in
patients with OHS in our study.
Although abundant levels of transcript were detected
by northern blots of the affected siblings’ mRNA, the
predicted protein is truncated and, thus, could be de-
graded, mislocalized, or both. Western blot analysis of
proteins from lymphoblastoid cell lines from the family
members, a normal control, and the female patient with
Menkes disease and translocation t(X;2)(q13;q32.2) who
is known as “CG” (Kapur et al. 1987; Verga et al. 1991)
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Figure 5 Western blot analysis of ATP7A levels. Protein from
lymphoblastoid cell lines from CG, II-6, III-1, III-2, and III-3 was
isolated according to a procedure described by Ambrosini andMercer
(1999). Fibroblast (Fb) protein from an unrelated normal control cell
line was isolated according to a procedure described by Dierick et al.
(1997). One hundred micrograms of protein per lane was fractionated
through a 7.5% acrylamide gel and then was electroblotted onto a
nitrocellulose membrane. This membrane was then hybridized with a
1:1,000 dilution of polyclonal a-ATP7A (upper panel), as described
by Dierick et al. (1997); after several washes in Tris buffered saline
solution plus Triton X-20, this membrane was incubated with a 1:
2,000 dilution of horseradish peroxidase–conjugated donkey anti-rab-
bit antibodies. a-ATP7A hybridized to a 174-kD protein in fibroblast,
consistent with ATP7A. Hybridization to a 174-kD protein in the
fibroblast cell line confirms that the ATP7A antibody is hybridizing to
the correct protein from lymphoblastoid cells. To demonstrate loading
consistency, the blot was hybridized with a 1:10,000 dilution of tub-
ulin-a Ab-2 antibody, which hybridized to a 57-kD protein. Ambrosini
and Mercer (1999) have reported smearing of ATP7A isolated from
lymphoblastoid cell lines and have suggested that it most likely was
a result of protein glycosylation.
Figure 6 Indirect immunofluorescence of ATP7A in fixed fibroblasts. Immunocytochemistry was performed according to a procedure
described by Dierick et al. (1997). Fibroblasts from II-1 (a), III-2 (b), and GM01981 (c) were incubated, for 1 h, with a 1:200 dilution of
polyclonal a-ATP7A (Dierick et al. 1997). To visualize the hybridization of a-ATP7A, the fibroblasts were incubated with a 1:1,000 dilution
of affinity-purified fluorescein isothiocyanate (HL) (Vector Laboratories). Cell nuclei were counterstained with 4’,6-diamidino-2-phenylindole.
Results were analyzed by a Zeiss Axioscope epifluorescence microscope and were documented by a Photometrics SenSys camera and Vysis
Quips imaging software (Applied Imaging).
revealed substantially less ATP7A in III-2 and III-3 (fig.
5, upper panel). No protein was detected in CG. Blots
were hybridized with tubulin-a Ab-2 antibody (Research
Antibody) as a loading control (fig. 5, lower panel). Serial
dilutions of normal control protein on western blots were
used to estimate that III-2 and III-3 have ∼100-fold less
ATP7A than is seen in normal controls. We propose that
the ATP7A truncation in the carboxy terminus may lead
to either misfolding or destabilization of the protein, re-
sulting in rapid degradation. The truncated protein, with
its 13 novel amino acids, may be conformationally in-
correct and rapidly degraded in the endoplasmic reticulum
(ER), which has a strict quality-control system for secre-
tory and membrane proteins (Zhang et al. 1997; Lord et
al. 2000). Alternatively, the carboxy terminus of ATP7A
may play a role in its metabolic stability after it exits the
ER. Rapid degradation has been observed in (a) protein
misfolding resulting from PTCmutations in the final exon
of a gene (Kainulainen et al. 1992) and (b) protein de-
stabilization resulting from a C-terminal–tail truncation
(Haardt et al. 1999). We postulate that a small percentage
of the truncated protein bypasses this quality-control sys-
tem. The western blot result is consistent with the findings
presented by Møller et al. (2000), which suggest that as
low as 2%–5% of functional ATP7A is sufficient to result
in themilder phenotype,OHS, rather than themore severe
phenotype, Menkes disease.
To verify these results and to attempt to localize the
truncated protein, we performed immunocytochemistry
on cultured fibroblasts. II-6 (not shown) and III-1 (fig.
6a) had normal ATP7A localization, to the perinuclear
region, consistent with TGN localization, in cells grown
in basal media. ATP7A was not detected in the TGN in
III-2 (fig. 6b), III-3 (not shown), or Menkes cell line
GM01981 (803del5nt; fig. 6c) (Das et al. 1994). Lack
of residual ATP7A perinuclear staining indicated that
ATP7A was either mislocalized or present at a level be-
low detection via immunocytochemistry (as would be
expected, on the basis of the western blot results). Co-
localization experiments with a-KDEL (Grp78; BiP),
which is ER specific, and with a-ATP7A demonstrated
that the truncated ATP7A was not mislocalized to the
ER (data not shown).
Ambrosini andMercer (1999) described a patientwith
classic Menkes disease who displayed only the OHS phe-
notype after early treatment with copper-histidine.West-
ern blot analysis indicated that this patient had normal
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levels of ATP7A—which was truncated within trans-
membrane domain (TMD) 7, thus deleting all of TMD8
and the carboxy tail, including the dileucine motif
L1487L1488. Immunocytochemistry of fibroblasts from
this patient, using an ATP7A antibody, displayed an
abundance, above background levels, of diffuse staining.
Ambrosini and Mercer (1999) surmised that the protein
was mislocalized—most likely to the plasma mem-
brane—owing to the loss of the endocytic signal. Since
ATP7A above background levels was not detected in
patients with OHS in our study (fig. 6), the immuno-
cytochemistry results support the western blot data and
demonstrate that the truncated protein is present at very
low levels.
This is the first demonstration, in OHS, of reduced
ATP7A at the protein level, but not at the mRNA level.
Our findings are consistent with other reports in which
reduced levels of functional ATP7A appear to be sufficient
to result in OHS; however, the mechanism reported here
is novel. In contrast to previous reports, transcript levels
are abundant, but the protein level is reduced. In addition,
the protein is abnormal and is truncated prior to the di-
leucine motif L1487L1488, which functions as an en-
docytic signal. This raises the question of whether the
dileucine motif is contributing to the OHS phenotype.
Recent data suggest that steady-state localization of
ATP7A to the TGN is necessary for proper activity of
lysyl oxidase (Ambrosini and Mercer 1999). It has been
hypothesized that, in OHS, the available ATP7A is mis-
localized—most likely to the plasma membrane—owing
to the low protein levels in relation to the increased
intracellular copper levels (Das et al. 1995), thus ex-
plaining the decreased lysyl oxidase activity. Our data
are consistent with both this hypothesis and the hy-
pothesis that the dileucine motif is not necessary for
maintenance of copper efflux from the cell. Because the
dileucine motif L14871488 is required for ATP7A to be
recycled back to the TGN, we would expect the majority
of the ATP7A present in our patients to be at the plasma
membrane.
In summary, patients with OHS in our study have a
deletion of a guanine in exon 23 of ATP7A, and this
deletion leads to a frameshift that results in 13 novel
amino acids before premature truncation of the protein,
prior to the dileucine motif L1487L1488. We have dem-
onstrated that these patients with OHS have abundant
ATP7A-transcript levels but reduced levels of a truncated
protein. This is the first report to show an ATP7A trun-
cation that does not result in Menkes disease. This study
supports data from Møller et al. (2000), which suggest
that as low as 2%–5% of normal levels of functional
ATP7A is sufficient to result in the milder phenotype,
OHS, rather than the more severe phenotype, Menkes
disease. Lower expression ofATP7A in these patientswith
OHS supports the hypothesis that lysyl oxidase is more
sensitive than other cuproenzymes are to copper defi-
ciency, owing to reduced levels of functionalATP7A (Das
et al. 1995; Levinson et al. 1996). The fact that our pa-
tients have OHS rather than Menkes disease supports the
hypothesis that the dileucine motif is not essential for
ATP7A activity in efflux of copper from the cell.
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